Silicon Valley has been trying to run a mile from the mess that is Theranos. But the debacle at the blood-testing start-up - which the US Securities and Exchange Commission said this week was a "massive fraud" - will not be as easy to shrug off as the powers-that-be in the tech world would like.
It also holds a particular warning at a time when tech start-ups are extending their reach into industries from healthcare to finance and transportation.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
